Rx (Prescription Medicine)
USD $ 120.00
USD $ 30.00 per injection
Bevazza 100mg Injection 是一种用于治疗特定类型癌症的靶向疗法。其活性成分为 bevacizumab，是一种重组人源化单克隆抗体，可抑制血管内皮生长因子（VEGF）。通过阻断 VEGF，Bevazza 可防止肿瘤生长和转移所需的新血管形成。这种作用机制称为抗血管生成，有助于减缓或停止肿瘤的进展。
Bevazza 适用于转移性结直肠癌、晚期非小细胞肺癌（非鳞状细胞）、复发性胶质母细胞瘤以及转移性肾细胞癌，常与化疗联合使用。Bevazza 的剂量和给药方式应由合格的医疗专业人员根据具体癌症类型、分期及个体患者因素决定。其给药方式为静脉注射。
常见不良反应可能包括高血压、蛋白尿、疲劳和鼻出血。更严重的不良反应可能发生，需要立即就医。患者应与医生讨论潜在风险和收益。Bevazza 应储存在 2°C 至 8°C 的冷藏环境中，并避光保存。禁止冷冻。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Pack Quantity | |
| Strength | |
| Brand Name | |
| Molecule | |
| Strength | 100 Mg |
| Medicine Form | Injection |
| Pack Quantity | 4 ML |
| Packaging Type | Vial / Bottle |
| Medicine Type | Generic |
| Country Of Origin | India |
| Rx Status | Rx (Prescription Medicine) |
其他品牌的 Bevacizumab 100 Mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
